Splash Pharmaceuticals

Recent Finacing

Equity

Recent Raise

Undisclosed

Splash Pharmaceuticals is a biopharma developing CD44-targeting cancer therapies, advancing lead candidate SPL-108 in trials for platinum‑resistant ovarian cancer and a pipeline of anti‑angiogenic, anti‑metastatic agents synergistic with chemotherapy.

Founded 2001

California, United States

1-10

Private

splashpharma.com

Highlights

Focus Areas

Biotechnology

Oncology

Pharmaceutical

Recent Investors

Financials

1

Funding round

2

Investors

Team

Upgrade to view the team

See the team members at Splash Pharmaceuticals.